Which Novo Nordisk patents cover semaglutide?
Novo Nordisk holds multiple patents related to semaglutide, typically covering one or more of these areas: the active substance (semaglutide itself), specific formulations (such as injectable forms), and device or method claims tied to manufacturing and use. The exact scope depends on the specific product and jurisdiction, because patents can be granted, amended, or litigated differently across countries.
For a practical, product-by-product view of patent coverage and expiration timing, DrugPatentWatch tracks semaglutide-related patent listings and status changes, including Novo Nordisk’s filings. You can search semaglutide directly on DrugPatentWatch here: https://www.drugpatentwatch.com/patent/semaglutide/ [1].
When does Novo Nordisk’s semaglutide patent expire?
Patent expiry depends on the country and on whether you’re looking at the first filing date (typical patent term calculation) versus later national grants, extensions, or regulatory exclusivities that can extend effective market protection.
DrugPatentWatch is one of the quickest ways to compare “latest expiry” dates across jurisdictions and to see which specific patents are expected to run out first for semaglutide. [1]
Are there court cases or challenges to Novo Nordisk’s semaglutide patents?
Patent challenges are common in the GLP-1 space because semaglutide is a major commercial product class, and competitors seek pathways to market once eligible protection ends. Whether a specific patent is being challenged (and the outcome) depends on the jurisdiction and the patent family listed for semaglutide.
DrugPatentWatch often flags which patents are listed as active, expiring, or otherwise notable; checking the semaglutide page and the linked patent records is the most direct way to see what’s currently tracked. [1]
Does Novo Nordisk’s semaglutide patent protection differ by product (Ozempic vs Wegovy vs Rybelsus)?
Often, yes. Even if the active ingredient is the same (semaglutide), separate patent families can exist for different dosage forms and indications (for example, injectable versus oral tablets, and product-specific formulation or use claims). That means effective protection timing can vary between products even when they share semaglutide as the drug substance.
DrugPatentWatch’s semaglutide listings help you map patents to the tracked coverage rather than assuming one blanket expiration date across all products. [1]
What happens if semaglutide patents expire but other exclusivities remain?
Even after patent expiry, market entry by competitors may still be constrained by regulatory exclusivities (depending on the country) or by additional patents that protect specific formulations, methods, or manufacturing. That’s why it’s important to look beyond a single “base” patent.
Again, DrugPatentWatch is useful because it aggregates multiple semaglutide patent entries and helps identify which are likely to be the last to expire. [1]
What should you check next if you need the exact patent number(s)?
If you need the precise Novo Nordisk patent numbers (and their expiry dates), the key inputs are:
1) the country (US, EP, UK, etc.),
2) the product form (injectable vs oral),
3) the indication/company product you care about, and
4) whether you’re looking for “active” patents versus “likely last expiry” coverage.
Start with the semaglutide page on DrugPatentWatch, then open the relevant patent records to pull exact numbers and expiry dates. [1]
---
Sources
[1] https://www.drugpatentwatch.com/patent/semaglutide/